Testing new treatments for inflammatory bowel disease using gut-targeted inhibitors
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD
This study is looking at new treatments that target a specific gene to help people with inflammatory bowel disease, like Crohn's disease and ulcerative colitis, by understanding how genetic differences can affect their risk and response to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10873229 on NIH RePORTER |
What this research studies
This research investigates the potential of novel gut-restricted inhibitors of the LRRK2 gene as therapies for inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis. The study aims to understand how genetic variations in LRRK2 influence disease risk and treatment response. By utilizing preclinical models, researchers will assess the effectiveness of these inhibitors in reducing inflammation and improving patient outcomes. The approach focuses on personalized medicine by considering genetic biomarkers that may guide treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Crohn's disease or ulcerative colitis, particularly those who have not achieved sustained remission with current therapies.
Not a fit: Patients with other gastrointestinal disorders or those who have not been diagnosed with inflammatory bowel disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatments for patients suffering from inflammatory bowel disease.
How similar studies have performed: Previous research has shown promise in targeting LRRK2 for treating related conditions, suggesting potential success for this novel approach in IBD.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Peter, Inga — Icahn School of Medicine at Mount Sinai
- Study coordinator: Peter, Inga
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.